Core Viewpoint - Shanghai Kelly Medical Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, indicating strong operational performance and growth potential in the medical technology sector [1][2]. Financial Performance - The company's operating income for the reporting period reached approximately 546.1 million yuan, representing a 14.75% increase compared to 475.9 million yuan in the same period last year [1]. - Net profit attributable to shareholders was approximately 43.8 million yuan, reflecting a 44.88% increase from 30.2 million yuan year-on-year [1]. - The net profit after deducting non-recurring gains and losses was about 45.1 million yuan, up 38.68% from 32.5 million yuan in the previous year [1]. - Basic earnings per share were reported at 0.0422 yuan, a decrease of 44.79% compared to 0.0611 yuan from the previous year [1]. Financial Position - Total assets at the end of the reporting period were approximately 3.35 billion yuan, showing a slight increase from 3.35 billion yuan at the end of the previous year [2]. - The net assets attributable to shareholders were approximately 2.77 billion yuan, up 1.68% from 2.72 billion yuan [2]. Shareholder Information - The top ten shareholders include various domestic investment companies, with the largest shareholder holding 6.99% of the shares [2][4]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5].
ST凯利: 2025年半年度报告摘要